Evaluating novel architectural proteins as therapeutic targets for cohesin dysfunction

点击翻译按钮获取中文摘要

Abstract Cornelia de Lange Syndrome (CdLS) is a rare developmental disorder affecting a multitude of organs including the central nervous system, inducing a variable neurodevelopmental delay. CdLS is primarily caused by mutations in regulatory or structural components of the cohesin complex, which are essential Structural Maintenance of Chromosomes (SMC) protein-containing complexes that interact with chromatin and modulate genome folding. It is hypothesized that CdLS symptoms are a consequence of transcriptional dysregulation due to changes in genome architecture upon cohesin disruption. To date, there are no therapies aimed at correcting cohesin dysfunction or chromatin misfolding directly. These issues are due, in part, to the paucity of factors known to regulate cohesin-mediated chromatin folding. We performed a high-throughput fluorescent in situ hybridization (Hi-FISH)-based screen in human cells, which uses Oligopaint probe technology to detect and measure chromatin interactions in a large number of samples. We targeted ~8,000 human genes, which represent the “druggable genome” and isolated five candidate genes whose depletion can offset cellular phenotypes associated with cohesin dysfunction. The goal of this proposal is to characterize the role of these novel ‘anti-cohesin factors’ in nuclear architecture and cohesin function and test the ability of their inhibition to correct gene misexpression in CdLS models. Through understanding the molecular factors involved in cohesin biology and chromatin folding, we can begin to consider targeted approaches to CdLS therapeutic development.